Chemed (CHE) Cost of Revenue (2009 - 2026)

Chemed has reported Cost of Revenue for 18 years, with the latest figure at $451.8 million in Q2 2026.

• Cost of Revenue for Q2 2026 came in at $451.8 million, up 4.07% year-over-year; the trailing twelve-month figure through Jun 2026 was $1.7 billion (up 4.14% YoY), and the FY2025 annual result was $1.7 billion, up 8.23% from the prior year.
• Cost of Revenue climbed to $451.8 million in Q2 2026, from $441.7 million in the prior quarter.
• Over five years, Cost of Revenue peaked at $451.8 million in Q2 2026 and troughed at $336.6 million in Q1 2022.
• A 5-year average of $389.6 million and a median of $387.4 million in 2024 frame the typical range for Cost of Revenue.
• The widest annual swing landed in 2022, when Cost of Revenue slipped 3.9%; it then advanced 13.26% in 2024.
• A 5-year view of Cost of Revenue shows it stood at $349.6 million in 2022, then climbed by 2.51% to $358.3 million in 2023, then advanced by 13.26% to $405.9 million in 2024, then gained by 2.04% to $414.2 million in 2025, then rose by 9.08% to $451.8 million in 2026.
• Per Business Quant data, the three most recent Cost of Revenue figures were $451.8 million in Q2 2026, $441.7 million in Q1 2026, and $414.2 million in Q4 2025.